AR088414A1 - Derivados sustituidos de indol - Google Patents
Derivados sustituidos de indolInfo
- Publication number
- AR088414A1 AR088414A1 ARP120101769A AR088414A1 AR 088414 A1 AR088414 A1 AR 088414A1 AR P120101769 A ARP120101769 A AR P120101769A AR 088414 A1 AR088414 A1 AR 088414A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted derivatives
- indol
- indol substituted
- po3h2
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
Abstract
La presente se refiere a derivados sustituidos de indol, a procedimientos para su producción, su uso como productos farmacéuticos y a composiciones farmacéuticas que los comprenden, útil para el tratamiento o prevención de enfermedades mediadas por quinasas, por ejemplo enfermedades inflamatorias; autoinmunes. Reivindicación 1: Un compuesto de la fórmula (1) o una sal o un hidrato farmacéuticamente aceptable, en donde X es CH o N; R es H o PO₃H₂; R¹ es H; o alquilo C₁₋₄; R² es H; o alquilo C₁₋₄; R³ es H; alquilo C₁₋₄; CN; Hal; u OH; y R⁴ y R⁵ son, independientemente entre sí, H, o alquilo C₁₋₄, o R⁴ y R⁵ forman junto con el átomo de carbono al que están unidos, un grupo cicloalquilo de 3 a 6 miembros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486808P | 2011-05-17 | 2011-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088414A1 true AR088414A1 (es) | 2014-06-11 |
Family
ID=46210333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101769 AR088414A1 (es) | 2011-05-17 | 2012-05-18 | Derivados sustituidos de indol |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8703782B2 (es) |
| EP (1) | EP2709998B1 (es) |
| JP (1) | JP6043344B2 (es) |
| KR (1) | KR20140023354A (es) |
| CN (1) | CN103534250B (es) |
| AR (1) | AR088414A1 (es) |
| AU (1) | AU2012257345B2 (es) |
| BR (1) | BR112013029416A2 (es) |
| CA (1) | CA2835169C (es) |
| EA (1) | EA023238B1 (es) |
| ES (1) | ES2565200T3 (es) |
| MX (1) | MX2013013436A (es) |
| TW (1) | TW201249858A (es) |
| UY (1) | UY34072A (es) |
| WO (1) | WO2012156936A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
| IN2015DN02660A (es) * | 2012-11-07 | 2015-09-04 | Novartis Ag | |
| DK3033086T3 (da) * | 2013-08-14 | 2022-01-03 | Novartis Ag | Kombinationsterapi til behandling af cancer |
| WO2015039187A1 (en) | 2013-09-18 | 2015-03-26 | University Of Canberra | Stem cell modulation ii |
| US10485772B2 (en) | 2014-08-25 | 2019-11-26 | EpiAxis Therapeutics Pty Ltd. | Compositions for modulating cancer stem cells and uses therefor |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925860A (en) | 1987-08-05 | 1990-05-15 | E. I. Du Pont De Nemours And Company | Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester |
| DE4005970A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| DK1224181T3 (da) | 1999-10-12 | 2004-04-13 | Hoffmann La Roche | Substituerede pyrroler som antiproliferative midler til behandling af cancer |
| AU2181002A (en) * | 2000-11-07 | 2002-05-21 | Novartis Ag | Indolylmaleimide derivatives as protein kinase c inhibitors |
| KR100937162B1 (ko) | 2001-12-21 | 2010-01-15 | 에이자이 아이엔씨. | 알콜 및 페놀의 수용성 포스포노옥시메틸 유도체를제조하는 방법 |
| RU2316317C2 (ru) | 2001-12-28 | 2008-02-10 | Эм-Джи-Ай Джи-Пи, Инк. | Составленные на основе воды фармацевтические композиции водорастворимых пролекарств пропофола |
| AR039209A1 (es) | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
| KR20070087004A (ko) | 2002-04-08 | 2007-08-27 | 엠쥐아이 쥐피, 아이엔씨. | 프로포폴의 수용성 프로드럭을 함유하는 약제학적 조성물및 그것을 투여하는 방법 |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| WO2004083202A1 (en) | 2003-03-19 | 2004-09-30 | Suven Life Sciences Limited | A process for the preparation of indolymaleimides |
| EP1856135B1 (en) | 2005-01-19 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| WO2007008514A2 (en) | 2005-07-07 | 2007-01-18 | Georgetown University | Inhibitors of glycogen synthase kinase 3 |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| GB0605691D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| EP2420505A1 (en) | 2006-11-21 | 2012-02-22 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses |
| WO2011057204A2 (en) | 2009-11-06 | 2011-05-12 | The Johns Hopkins University | Lrrk2-mediated neuronal toxicity |
| CN101812097B (zh) | 2010-04-17 | 2012-04-25 | 中国海洋大学 | 吲哚咔唑和双吲哚马来酰亚胺生物碱及其制备方法和应用 |
| UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
-
2012
- 2012-05-14 UY UY34072A patent/UY34072A/es not_active Application Discontinuation
- 2012-05-15 US US13/471,512 patent/US8703782B2/en active Active
- 2012-05-16 AU AU2012257345A patent/AU2012257345B2/en active Active
- 2012-05-16 CN CN201280023473.2A patent/CN103534250B/zh active Active
- 2012-05-16 EA EA201391710A patent/EA023238B1/ru not_active IP Right Cessation
- 2012-05-16 BR BR112013029416A patent/BR112013029416A2/pt not_active IP Right Cessation
- 2012-05-16 WO PCT/IB2012/052473 patent/WO2012156936A1/en active Application Filing
- 2012-05-16 TW TW101117465A patent/TW201249858A/zh unknown
- 2012-05-16 ES ES12726226.9T patent/ES2565200T3/es active Active
- 2012-05-16 EP EP12726226.9A patent/EP2709998B1/en active Active
- 2012-05-16 CA CA2835169A patent/CA2835169C/en active Active
- 2012-05-16 KR KR20137030038A patent/KR20140023354A/ko not_active Application Discontinuation
- 2012-05-16 JP JP2014510933A patent/JP6043344B2/ja active Active
- 2012-05-16 MX MX2013013436A patent/MX2013013436A/es not_active Application Discontinuation
- 2012-05-18 AR ARP120101769 patent/AR088414A1/es not_active Application Discontinuation
-
2014
- 2014-03-03 US US14/194,879 patent/US9029396B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA023238B1 (ru) | 2016-05-31 |
| US9029396B2 (en) | 2015-05-12 |
| MX2013013436A (es) | 2013-12-06 |
| JP6043344B2 (ja) | 2016-12-14 |
| CN103534250B (zh) | 2016-05-11 |
| EA201391710A1 (ru) | 2014-03-31 |
| TW201249858A (en) | 2012-12-16 |
| AU2012257345B2 (en) | 2016-03-24 |
| CA2835169C (en) | 2019-05-14 |
| BR112013029416A2 (pt) | 2017-01-31 |
| WO2012156936A1 (en) | 2012-11-22 |
| CN103534250A (zh) | 2014-01-22 |
| US8703782B2 (en) | 2014-04-22 |
| UY34072A (es) | 2013-01-03 |
| JP2014518870A (ja) | 2014-08-07 |
| CA2835169A1 (en) | 2012-11-22 |
| EP2709998B1 (en) | 2016-01-06 |
| ES2565200T3 (es) | 2016-04-01 |
| EP2709998A1 (en) | 2014-03-26 |
| KR20140023354A (ko) | 2014-02-26 |
| US20130157980A1 (en) | 2013-06-20 |
| US20140179634A1 (en) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| AR093937A1 (es) | Compuestos quimicos | |
| AR098912A1 (es) | Inhibidores de syk | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| AR083069A1 (es) | Analogos de nucleotidos sustituidos | |
| AR086522A1 (es) | Inhibidores heterociclicos de autotaxina y usos de los mismos | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| BR112016010080A8 (pt) | compostos de pirazolopirimidina, composição farmacêutica e seu uso | |
| AR088000A1 (es) | Derivados de pirazolquinolinona, su preparacion y su uso terapeutico | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| BR112013021941A2 (pt) | agente terapêutico para tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |